June 2, 2021 07:42 AM EDTUpdated 10:59 AM

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Germany’s MorphoSys has swooped in to buy cancer drug developer Constellation $CNST in a deal that values the company at $1.7 billion. And they’re funding …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Amgen names Stanford geneticist and biotech founder to CSO post

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

Are programs with compounded GLP-1s safe for your population?

Mor­phoSys swoops in with a $1.7B deal to buy Con­stel­la­tion, adds $2B-plus in Roy­al­ty pact

Editor & Founder

Editor

Sign up to read this article for free.

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact